The DOI matches its Crossref record; 200 of the 200 references it cites were found in a registry or an index.
Tamoxifen, Raloxifene, and the Prevention of Breast Cancer*
Abstract
IN 1896, George Beatson demonstrated that the removal of the ovaries from premenopausal women with metastatic breast cancer could, in some cases, cause regression of the disease and improve the prognosis of the patient (1). However, by 1900 Stanley Boyd had established that only one in three patients would obtain improvement for about 1 yr (2). Despite this disappointment, a link was established between an ovarian factor and the growth of some breast cancers. This observation was to become the foundation of modern clinical practice and the rationale for the use of antiestrogens to treat breast cancer (3, 4). At the turn of the century, studies were being conducted in the laboratory to complement the clinical effort. Inbred strains of mice were being established for medical research, and it was found that certain strains of mice developed a high incidence of mammary tumors. Lathrop and Loeb (5) reported that an early ovariectomy could prevent the spontaneous development of tumors but it was not until Allen and Doisey (6) identified “estrus stimulating principle” that ovarian hormones could be linked to the development of breast cancer. By 1936, Professor Antoine Lacassagne, again working with high-incidence strains of mice, suggested that if breast cancer was caused by a special hereditary sensitivity to estrogen, then the disease could be prevented by developing a therapeutic antagonist to estrogen action in the breast (7). However, there were no therapeutic antagonists of estrogen at that time, nor was there a target to design drug molecules. Nevertheless, exciting developments in the discovery of nonsteroidal estrogens would establish the structural basis of carrier molecules, which resulted in the design of the two drugs, tamoxifen and raloxifene (Fig. 1), both originally described as antiestrogens and used today in a clinical trial to prevent breast cancer in high-risk women (see Section IX).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,775
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,071
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
Cloning of a novel receptor expressed in rat prostate and ovary.
Kuiper, G. G., Enmark, E., Pelto-Huikko, M., Nilsson, S., & Gustafsson, J. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.5925 · Cited by 4,788
Kuiper, G. G. J. M., Carlsson, B., Grandien, K., Enmark, E., Häggblad, J., Nilsson, S., & Gustafsson, J.-A. (1997) · Endocrinology · doi:10.1210/endo.138.3.4979 · Cited by 4,442
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
Gail, M. H., Brinton, L. A., Byar, D. P., Corle, D. K., Green, S. B., Schairer, C., & Mulvihill, J. J. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.24.1879 · Cited by 3,334
MOLECULAR MECHANISMS OF ACTION OF STEROID/THYROID RECEPTOR SUPERFAMILY MEMBERS
Tsai, M.-J., & O'Malley, B. W. (1994) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.63.070194.002315 · Cited by 2,932
Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., & Greene, G. L. (1998) · Cell · doi:10.1016/s0092-8674(00)81717-1 · Cited by 2,729
A Human Cell Line From a Pleural Effusion Derived From a Breast Carcinoma 2
Soule, H. D., Vazquez, J., Long, A., Albert, S., & Brennan, M. (1973) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/51.5.1409 · Cited by 2,449
Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily
Oñate, S. A., Tsai, S. Y., Tsai, M.-J., & O'Malley, B. W. (1995) · Science · doi:10.1126/science.270.5240.1354 · Cited by 2,387
Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A
Green, S., Walter, P., Kumar, V., Krust, A., Bornert, J.-M., Argos, P., & Chambon, P. (1986) · Nature · doi:10.1038/320134a0 · Cited by 2,321
The Risk of Cancer Associated with Specific Mutations of BRCA1 and BRCA2 among Ashkenazi Jews
Struewing, J. P., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., Brody, L. C., & Tucker, M. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362001 · Cited by 2,281
Armstrong, B., & Doll, R. (1975) · International Journal of Cancer · doi:10.1002/ijc.2910150411 · Cited by 2,151
Localization of a Breast Cancer Susceptibility Gene, BRCA2 , to Chromosome 13q12-13
Wooster, R., Neuhausen, S. L., Mangion, J., Quirk, Y., Ford, D., Collins, N., Nguyen, K., Seal, S., Tran, T., Averill, D., et al. (1994) · Science · doi:10.1126/science.8091231 · Cited by 1,924
Differential Ligand Activation of Estrogen Receptors ERα and ERβ at AP1 Sites
Paech, K., Webb, P., Kuiper, G. G. J. M., Nilsson, S., Gustafsson, J.-Å., Kushner, P. J., & Scanlan, T. S. (1997) · Science · doi:10.1126/science.277.5331.1508 · Cited by 1,861
Risk Factors for Breast Cancer in Women with Proliferative Breast Disease
Dupont, W. D., & Page, D. L. (1985) · New England Journal of Medicine · doi:10.1056/nejm198501173120303 · Cited by 1,829
Steroid hormone receptors: Many Actors in search of a plot
Beato, M., Herrlich, P., & Schütz, G. (1995) · Cell · doi:10.1016/0092-8674(95)90201-5 · Cited by 1,823
Delmas, P. D., Bjarnason, N. H., Mitlak, B. H., Ravoux, A.-C., Shah, A. S., Huster, W. J., Draper, M., & Christiansen, C. (1997) · New England Journal of Medicine · doi:10.1056/nejm199712043372301 · Cited by 1,637
Beatson, G. (1896) · The Lancet · doi:10.1016/s0140-6736(01)72384-7 · Cited by 1,608
Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells
King, W. J., & Greene, G. L. (1984) · Nature · doi:10.1038/307745a0 · Cited by 1,400
Tamoxifen in the Treatment of Breast Cancer
Osborne, C. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811263392207 · Cited by 1,320
Functional domains of the human estrogen receptor
Kumar, V., Green, S., Stack, G., Berry, M., Jin, J.-R., & Chambon, P. (1987) · Cell · doi:10.1016/0092-8674(87)90581-2 · Cited by 1,316
Sequence and Expression of Human Estrogen Receptor Complementary DNA
Greene, G. L., Gilna, P., Waterfield, M., Baker, A., Hort, Y., & Shine, J. (1986) · Science · doi:10.1126/science.3753802 · Cited by 1,311
Beatson, G. (1896) · The Lancet · doi:10.1016/s0140-6736(01)72307-0 · Cited by 1,282
Fisher, B., Costantino, J. P., Redmond, C. K., Fisher, E. R., Wickerham, D. L., Cronin, W. M., & Contributors, O. N. (1994) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/86.7.527 · Cited by 1,268
Easton, D. F., Bishop, D. T., Ford, D., & Crockford, G. P. (1993) · Europe PMC (PubMed Central) · Cited by 1,243
The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer
Kumar, V., & Chambon, P. (1988) · Cell · doi:10.1016/0092-8674(88)90017-7 · Cited by 1,220
Effects of Tamoxifen on Bone Mineral Density in Postmenopausal Women with Breast Cancer
Love, R. R., Mazess, R. B., Barden, H. S., Epstein, S., Newcomb, P. A., Jordan, V. C., Carbone, P. P., & DeMets, D. L. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203263261302 · Cited by 1,129
Self-citationAge at first birth and breast cancer risk.
MacMahon, B., Cole, P. T., Lin, T. M., Lowe, C. R., Mirra, A. P., Ravnihar, B., Salber, E. J., Valaoras, V. G., & Yuasa, S. (1970) · Europe PMC (PubMed Central) · Cited by 1,057
A two-step mechanism for the interaction of estradiol with rat uterus.
Jensen, E. V., Suzuki, T., Kawashima, T., Stumpf, W. E., Jungblut, P. W., & DeSombre, E. R. (1968) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.59.2.632 · Cited by 1,015
Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids).
Sporn, M. B., Dunlop, N. M., Newton, D. L., & Smith, J. M. (1976) · PubMed · Cited by 992
Nuclear receptor coactivators and corepressors
Horwitz, K. B. (1996) · Molecular Endocrinology · doi:10.1210/me.10.10.1167 · Cited by 942
Effects of Adjuvant Tamoxifen and of Cytotoxic Therapy on Mortality in Early Breast Cancer
Early Breast Cancer Trialists' Collaborative Group (1988) · New England Journal of Medicine · doi:10.1056/nejm198812293192601 · Cited by 933
Genetic analysis of breast cancer in the cancer and steroid hormone study.
Claus, E. B., RISCH, N. J., & Thompson, W. D. (1991) · PubMed · Cited by 911
Powles, T. (1998) · The Lancet · doi:10.1016/s0140-6736(98)05071-5 · Cited by 902
Nuclear localization of unoccupied oestrogen receptors
Welshons, W. V., Lieberman, M. E., & Gorski, J. (1984) · Nature · doi:10.1038/307747a0 · Cited by 871
Fisher, B., Dignam, J., Bryant, J., DeCillis, A., Wickerham, D. L., Wolmark, N., Costantino, J., Redmond, C., Fisher, E. R., Bowman, D. M., et al. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.21.1529 · Cited by 861
Lippman, M. E., Bolan, G., & Huff, K. K. (1976) · PubMed · Cited by 810
Veronesi, U. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04394-3 · Cited by 804
初期食道静脈りゅう治療におけるテルイプレシン(グリプレシン)とバソプレシンの比較試験
Freeman, J. G., Cobden, I., Lishman, A. H., & Record, C. O. (1982) · The Lancet · Cited by 773
Berry, M., Metzger, D., & Chambon, P. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07469.x · Cited by 767
Cloning of the human estrogen receptor cDNA.
Walter, P., Green, S., Greene, G., Krust, A., Bornert, J. M., Jeltsch, J. M., Staub, A., Jensen, E., Scrace, G., & Waterfield, M. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.23.7889 · Cited by 730
A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474
Cole, M. P., Jones, C. T. A., & Todd, I. D. H. (1971) · British Journal of Cancer · doi:10.1038/bjc.1971.33 · Cited by 701
Basic Guide to the Mechanisms of Antiestrogen Action
Macgregor, J. I., & Jordan, V. C. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01358-9 · Cited by 694
Self-citationWebb, P. (1995) · Molecular Endocrinology · doi:10.1210/me.9.4.443 · Cited by 693
Effects of Raloxifene on Serum Lipids and Coagulation Factors in Healthy Postmenopausal Women
Walsh, B. W. (1998) · JAMA · doi:10.1001/jama.279.18.1445 · Cited by 692
A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization.
Toft, D., & Gorski, J. (1966) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.55.6.1574 · Cited by 680
Tzukerman, M. T. (1994) · Molecular Endocrinology · doi:10.1210/me.8.1.21 · Cited by 671
Estrogen Receptors in Human Breast Cancer
McGuire, W. L. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107175 · Cited by 668
Smith, C. S., Nawaz, Z., & O’Malley, B. W. (1997) · Molecular Endocrinology · doi:10.1210/me.11.6.657 · Cited by 662
Cohort Studies of Fat Intake and the Risk of Breast Cancer — A Pooled Analysis
Hunter, D. J., Spiegelman, D., Adami, H.-O., Beeson, L., van den Brandt, P. A., Folsom, A. R., Fraser, G. E., Goldbohm, R. A., Graham, S., Howe, G. R., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602083340603 · Cited by 657
Proportion of Breast Cancer Cases in the United States Explained by Well-Established Risk Factors
Madigan, M. P., Ziegler, R. G., Benichou, J., Byrne, C., & Hoover, R. N. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.22.1681 · Cited by 655
Powles, T. J., Hickish, T., Kanis, J. A., Tidy, A., & Ashley, S. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.78 · Cited by 646
Estrogen Receptor-Associated Proteins: Possible Mediators of Hormone-Induced Transcription
Halachmi, S., Marden, E., Martin, G., MacKay, H., Abbondanza, C., & Brown, M. (1994) · Science · doi:10.1126/science.8197458 · Cited by 637
A Meta-analysis of the Effect of Estrogen Replacement Therapy on the Risk of Breast Cancer
Steinberg, K. K. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03460150089030 · Cited by 626
Estrogen Receptors in Human Breast Cancer
Powles, T. (1976) · Journal of Clinical Pathology · doi:10.1136/jcp.29.5.467-d · Cited by 614
Black, L. J., Sato, M., Rowley, E. R., Magee, D. E., Bekele, A., Williams, D. C., Cullinan, G. J., Bendele, R., Kauffman, R. F., & Bensch, W. R. (1994) · Journal of Clinical Investigation · doi:10.1172/jci116985 · Cited by 609
Gordon, D. (1976) · The Lancet · doi:10.1016/s0140-6736(76)92329-1 · Cited by 552
Monoclonal antibodies to human estrogen receptor.
Greene, G. L., Nolan, C., Engler, J. P., & Jensen, E. V. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.9.5115 · Cited by 539
Katzenellenbogen, J. A. (1996) · Molecular Endocrinology · doi:10.1210/me.10.2.119 · Cited by 535
Kedar, R., Bourne, T. H., Collins, W. P., Campbell, S., Powles, T. J., Ashley, S., & Cosgrove, D. O. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92466-x · Cited by 531
Kumar, V., Green, S., Staub, A., & Chambon, P. (1986) · The EMBO Journal · doi:10.1002/j.1460-2075.1986.tb04489.x · Cited by 530
Hormone Receptors: Studies on the Interaction of Estrogen with the Uterus
GORSKI, J., TOFT, D., SHYAMALA, G., SMITH, D., & NOTIDES, A. (1968) · Proceedings of the 1967 Laurentian Hormone Conference · doi:10.1016/b978-1-4831-9827-9.50008-3 · Cited by 530
Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens
McDonnell, D. P. (1995) · Molecular Endocrinology · doi:10.1210/me.9.6.659 · Cited by 526
Lactation and a Reduced Risk of Premenopausal Breast Cancer
Newcomb, P. A., Storer, B. E., Longnecker, M. P., Mittendorf, R., Greenberg, E. R., Clapp, R. W., Burke, K. P., Willett, W. C., & MacMahon, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199401133300201 · Cited by 522
Newman, B., Austin, M. A., Lee, M., & King, M. C. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.9.3044 · Cited by 515
OEstrogenic Activity of Certain Synthetic Compounds
DODDS, E. C., GOLDBERG, L., LAWSON, W., & ROBINSON, R. (1938) · Nature · doi:10.1038/141247b0 · Cited by 514
A MONOHYDROXYLATED METABOLITE OF TAMOXIFEN WITH POTENT ANTIOESTROGENIC ACTIVITY
JORDAN, V. C., COLLINS, M. M., ROWSBY, L., & PRESTWICH, G. (1977) · Journal of Endocrinology · doi:10.1677/joe.0.0750305 · Cited by 506
Self-citationALLEN, E., & DOISY, E. A. (1923) · Journal of the American Medical Association · doi:10.1001/jama.1923.02650100027012 · Cited by 479
Jackson, T. A., Richer, J. K., Bain, D. L., Takimoto, G. S., Tung, L. W., & Horwitz, K. B. (1997) · Molecular Endocrinology · doi:10.1210/me.11.6.693 · Cited by 478
Physical Exercise and Reduced Risk of Breast Cancer in Young Women
Bernstein, L., Henderson, B. E., Hanisch, R., Sullivan-Halley, J., & Ross, R. K. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.18.1403 · Cited by 472
Delayed Menarche and Amenorrhea of College Athletes in Relation to Age of Onset of Training
Frisch, R. E. (1981) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1981.03320140047029 · Cited by 455
Approaches to prevention of epithelial cancer during the preneoplastic period.
Sporn, M. B. (1976) · PubMed · Cited by 445
A NEW DERIVATIVE OF TRIPHENYLETHYLENE: EFFECT ON IMPLANTATION AND MODE OF ACTION IN RATS
HARPER, M. J. K., & WALPOLE, A. L. (1967) · Reproduction · doi:10.1530/jrf.0.0130101 · Cited by 445
Oestradiol induction of a glucocorticoid-responsive gene by a chimaeric receptor
Green, S., & Chambon, P. (1987) · Nature · doi:10.1038/325075a0 · Cited by 431
Yang, N. N., Venugopalan, M., Hardikar, S., & Glasebrook, A. (1996) · Science · doi:10.1126/science.273.5279.1222 · Cited by 429
Adjuvant tamoxifen in the management of operable breast cancer : Scottish Trial
Scottish Cancer Trials Office (1987) · The Lancet · Cited by 428
Estrogen receptors and breast cancer response to adrenalectomy.
Jensen, E. V., Block, G. E., Smith, S. B., Kyser, K., & DeSombre, E. R. (1971) · PubMed · Cited by 423
Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse.
Gottardis, M. M., Robinson, S. P., SATYASWAROOP, P. G., & Jordan, V. C. (1988) · PubMed · Cited by 422
Self-citationMenopause and Breast Cancer Risk 2
(1972) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/48.3.605 · Cited by 421
Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture.
Lerner, L. J., & Jordan, V. C. (1990) · PubMed · Cited by 417
Self-citationBiochemical pharmacology of antiestrogen action.
Jordan, V. C. (1984) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06650-5 · Cited by 417
Self-citationEstrogen Receptor in a Human Cell Line (MCF-7) from Breast Carcinoma
Brooks, S. C., Locke, E. R., & Soule, H. D. (1973) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)43537-0 · Cited by 413
MCF-7: the first hormone-responsive breast cancer cell line.
Levenson, A. S., & Jordan, V. C. (1997) · PubMed · Cited by 410
Self-citationEffect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice.
Osborne, C. K., Hobbs, K., & Clark, G. M. (1985) · PubMed · Cited by 402
Endocrine Pharmacology of Antiestrogens as Antitumor Agents*
JORDAN, V. C., & MURPHY, C. S. (1990) · Endocrine Reviews · doi:10.1210/edrv-11-4-578 · Cited by 400
Self-citationp300 is a component of an estrogen receptor coactivator complex.
Hanstein, B., Eckner, R., DiRenzo, J., Halachmi, S., Liu, H., Searcy, B., Kurokawa, R., & Brown, M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11540 · Cited by 396
Coezy, E. D., Borgna, J., & Rochefort, H. (1982) · PubMed · Cited by 394
Gottardis, M. M., & Jordan, V. C. (1987) · PubMed · Cited by 378
Self-citationAnti-oestrogen Therapy for Breast Cancer: A Trial of Tamoxifen at Two Dose Levels
Ward, H. W. C. (1973) · BMJ · doi:10.1136/bmj.1.5844.13 · Cited by 375
Effects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal Women
Love, R. R., Wiebe, D. A., Newcomb, P. A., Cameron, L., Leventhal, H., Jordan, V. C., Feyzi, J., & DeMets, D. L. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-11-860 · Cited by 374
Self-citationEffect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata
Jordan, V. C. (1976) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(76)90030-x · Cited by 371
Self-citationA Meta-analysis of Alcohol Consumption in Relation to Risk of Breast Cancer
Longnecker, M. P. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03410050072032 · Cited by 368
McDonald, C. C., & Stewart, H. J. (1991) · BMJ · doi:10.1136/bmj.303.6800.435 · Cited by 365
Miller, A. B., Howe, G. R., Sherman, G. J., Lindsay, J. P., Yaffe, M. J., Dinner, P. J., Risch, H. A., & Preston, D. L. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911093211902 · Cited by 363
Butta, A., MacLennan, K., Flanders, K. C., Sacks, N. P. M., Smith, I., McKinna, A., Dowsett, M., Wakefield, L. M., Sporn, M. B., & Baum, M. (1992) · PubMed · Cited by 343
Rutqvist, L. E., & Anders Mattsson for the Stockholm Breast Cancer Study Group (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.17.1398 · Cited by 334
Effects of anti-estrogens on bone in castrated and intact female rats
Jordan, V. C., Phelps, E., & Lindgren, J. U. (1987) · Breast Cancer Research and Treatment · doi:10.1007/bf01806132 · Cited by 324
Self-citationColletta, A., Wakefield, L., Howell, F., van Roozendaal, K., Danielpour, D., Ebbs, Sr., Sporn, M., & Baum, M. (1990) · British Journal of Cancer · doi:10.1038/bjc.1990.307 · Cited by 318
Molecular Biology of the Human T-Lymphotropic Retroviruses
Wong-Staal, F. (1986) · New Experimental Modalities in the Control of Neoplasia · doi:10.1007/978-1-4684-5242-6_24 · Cited by 317
Influence of Synthetic Oestrogens on Advanced Malignant Disease
Haddow, A., Watkinson, J., Paterson, E., & KOLLER, P. C. (1944) · BMJ · doi:10.1136/bmj.2.4368.393 · Cited by 299
Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats.
Greaves, P., Goonetilleke, R., Nunn, G., Topham, J. C., & Orton, T. C. (1993) · PubMed · Cited by 298
Layde, P. M., Webster, L. A., Baughman, A. L., Wingo, P. A., Rubin, G. L., & Ory, H. W. (1989) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(89)90161-3 · Cited by 288
Jones, C. D., Jevnikar, M. G., Pike, A. J., Peters, M. K., Black, L. J., Thompson, A. R., Falcone, J. F., & Clemens, J. A. (1984) · Journal of Medicinal Chemistry · doi:10.1021/jm00374a021 · Cited by 283
Sato, M., Rippy, M. K., & Bryant, H. U. (1996) · The FASEB Journal · doi:10.1096/fasebj.10.8.8666168 · Cited by 277
McDonald, C. C., Alexander, F. E., Whyte, B. W., Forrest, A. P., & Stewart, H. J. (1995) · BMJ · doi:10.1136/bmj.311.7011.977 · Cited by 276
Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator.
McInerney, E. M., Tsai, M. J., O'Malley, B. W., & Katzenellenbogen, B. S. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.19.10069 · Cited by 256
The Risk of Breast Cancer after Irradiation of the Thymus in Infancy
Hildreth, N. G., Shore, R. E., & Dvoretsky, P. M. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911093211901 · Cited by 252
'Nolvadex', A. A. E. Y. B., & Adjuvant Trial Organisation. (1988) · British Journal of Cancer · doi:10.1038/bjc.1988.138 · Cited by 250
Inherited p53 gene mutations in breast cancer.
Sidransky, D., Tokino, T., Helzlsouer, K. J., et al. (1992) · PubMed · Cited by 249
Powles, T., Hardy, Jr., Ashley, S., Farrington, G., Cosgrove, D., Davey, J., Dowsett, M., McKinna, J., Nash, A., Sinnett, H., et al. (1989) · British Journal of Cancer · doi:10.1038/bjc.1989.235 · Cited by 246
Molecular determinants of tissue selectivity in estrogen receptor modulators
Grese, T. A., Sluka, J. P., Bryant, H. U., Cullinan, G. J., Glasebrook, A. L., Jones, C. D., Matsumoto, K., Palkowitz, A. D., Sato, M., Termine, J. D., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.25.14105 · Cited by 243
Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats
Turner, R. T., Wakley, G. K., Hannon, K. S., & Bell, N. H. (1987) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650020513 · Cited by 242
Antagonism of estrogen action with a new benzothiophene derived antiestrogen
Black, L. J., Jones, C. D., & Falcone, J. F. (1983) · Life Sciences · doi:10.1016/0024-3205(83)90935-9 · Cited by 239
Prospective Study of Relative Weight, Height, and Risk of Breast Cancer
London, S. J. (1989) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1989.03430200097033 · Cited by 236
Inherited breast and ovarian cancer. What are the risks? What are the choices?
King, M. (1993) · JAMA · doi:10.1001/jama.269.15.1975 · Cited by 236
A prospective study in general practice on breast‐cancer risk in postmenopausal women
de Waard, F., & Baanders‐Van Halewijn, E. A. (1974) · International Journal of Cancer · doi:10.1002/ijc.2910140203 · Cited by 235
LERNER, L. J., HOLTHAUS, F. J., & THOMPSON, C. R. (1958) · Endocrinology · doi:10.1210/endo-63-3-295 · Cited by 233
Norris, J., Fan, D., Aleman, C., Marks, J. R., Futreal, P. A., Wiseman, R. W., Iglehart, J. D., Deininger, P. L., & McDonnell, D. P. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.39.22777 · Cited by 231
A receptor molecule for estrogens: studies using a cell-free system.
Toft, D., Shyamala, G., & Gorski, J. (1967) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.57.6.1740 · Cited by 224
Jordan, V. C., & Allen (née Naylor), K. E. (1980) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(80)90156-5 · Cited by 214
Self-citationFamily History, Age, and Risk of Breast Cancer: Prospective Data From the Nurses' Health Study
Colditz, G. A. (1993) · JAMA · doi:10.1001/jama.1993.03510030062035 · Cited by 211
Induced Abortion and the Risk of Breast Cancer
Melbye, M., Wohlfahrt, J., Olsen, J. H., Frisch, M., Westergaard, T., Helweg-Larsen, K., & Andersen, P. K. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701093360201 · Cited by 210
Monoclonal antibodies to estrophilin: probes for the study of estrogen receptors.
Greene, G. L., Fitch, F. W., & Jensen, E. V. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.1.157 · Cited by 206
Kraus, W. L., McInerney, E. M., & Katzenellenbogen, B. S. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.26.12314 · Cited by 203
Hormonal Pathogenesis of Adenocarcinoma of the Breast
Lacassagne, A. (1936) · The American Journal of Cancer · doi:10.1158/ajc.1936.217 · Cited by 194
Effects of Tamoxifen on Spinal Bone Density in Women With Breast Cancer
Turken, S., Siris, E., Seldin, D., Flaster, E., Hyman, G., & Lindsay, R. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.14.1086 · Cited by 194
Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor
Jordan, V. C., & Koerner, S. (1975) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(75)90119-x · Cited by 186
Self-citationEstrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice.
SATYASWAROOP, P. G., Zaino, R. J., & Mortel, R. (1984) · PubMed · Cited by 178
Clemens, J. A., Bennett, D. R., Black, L. J., & Jones, C. D. (1983) · Life Sciences · doi:10.1016/0024-3205(83)90323-5 · Cited by 176
Grese, T. A., Cho, S., Finley, D. R., Godfrey, A. G., Jones, C. D., Lugar, C. W., Martin, M. J., Matsumoto, K., Pennington, L. D., Winter, M. A., et al. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm9606352 · Cited by 176
Raloxifene preserves bone strength and bone mass in ovariectomized rats
Turner, C. H. (1994) · Endocrinology · doi:10.1210/en.135.5.2001 · Cited by 173
MEIRIK, O. (1986) · The Lancet · doi:10.1016/s0140-6736(86)90166-2 · Cited by 171
Anzano, M. A., Peer, C. W., Smith, J. M., Mullen, L. T., Shrader, M. W., Logsdon, D. L., Driver, C. L., Brown, C. C., Roberts, A. B., & Sporn, M. B. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.2.123 · Cited by 170
Lack of Effect of Raloxifene on Coronary Artery Atherosclerosis of Postmenopausal Monkeys1
Clarkson, T. B., Anthony, M. S., & Jerome, C. P. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.3.4617 · Cited by 170
Tamoxifen (Antiestrogen) Therapy in Advanced Breast Cancer
KIANG, D. T., & KENNEDY, B. (1977) · Annals of Internal Medicine · doi:10.7326/0003-4819-87-6-687 · Cited by 166
Coronary Heart Disease Mortality and Adjuvant Tamoxifen Therapy
Costantino, J. P., Dignam, J. J., Kuller, L. H., Ives, D. G., & Fisher, B. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.11.776 · Cited by 163
Menopausal hormone replacement therapy and breast cancer: A meta‐analysis
Sillero‐Arenas, M., Delgado‐Rodriquez, M., Rodigues-Canteras, R., Bueno‐Cavanillas, A., & Gálvez-Vargas, R. (1992) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(92)90949-j · Cited by 161
Risk of Breast Cancer Among Young Women: Relationship to Induced Abortion
Daling, J. R., Malone, K. E., Voigt, L. F., White, E., & Weiss, N. S. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.21.1584 · Cited by 160
Prevention of breast cancer with tamoxifen—an update on the royal Marsden Hospital pilot programme
Powles, T. J., Tillyer, C. R., Jones, A. L., Ashley, S. E., Treleaven, J., Davey, J. B., & Alan McKinna, J. (1990) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(90)90116-b · Cited by 159
ORAL CONTRACEPTIVE USE AND BREAST CANCER RISK IN YOUNG WOMEN
UKNATIONALCASECONTROLSTUDYGRO (1989) · The Lancet · doi:10.1016/s0140-6736(89)92627-5 · Cited by 159
Increased Risk of Breast Cancer with Alcohol Consumption in Postmenopausal Women
Gapstur, S. M., Potter, J. D., Sellers, T. A., & Folsom, A. R. (1992) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116430 · Cited by 159
The Royal Marsden Hospital pilot tamoxifen chemoprevention trial
Powles, T. J., Jones, A. L., Ashley, S. E., O'Brien, M. E. R., Tidy, V. A., Treleavan, J., Cosgrove, D. O., Nash, A. G., Sacks, N., Baum, M., et al. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00689678 · Cited by 155
Wolf, D. M., & Jordan, V. C. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00689683 · Cited by 155
Self-citationA Different Perspective on Breast Cancer Risk Factors: Some Implications of the Nonattributable Risk
Seidman, H., Stellman, S. D., & Mushinski, M. H. (1982) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.32.5.301 · Cited by 154
Yang, N., Bryant, H. U., Hardikar, S., Sato, M., Galvin, R. J., Glasebrook, A. L., & Termine, J. D. (1996) · Endocrinology · doi:10.1210/endo.137.5.8612550 · Cited by 145
Frolik, C. A., Bryant, H. U., Black, E. C., Magee, D. E., & Chandrasekhar, S. (1996) · Bone · doi:10.1016/8756-3282(96)00085-3 · Cited by 144
Effects of raloxifene hydrochloride on the endometrium of postmenopausal women
Boss, S. M., Huster, W. J., Neild, J. A., Glant, M. D., Eisenhut, C. C., & Draper, M. W. (1997) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(97)70091-7 · Cited by 144
A realistic clinical perspective of tamoxifen and endometrial carcinogenesis
Assikis, V. J., Neven, P., Jordan, V. C., et al. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00184-0 · Cited by 142
Self-citationRemodeling the estrogen receptor model
Gorski, J., Welshons, W. V., & Sakai, D. D. (1984) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(84)90079-0 · Cited by 141
Gonadotrophin Inhibiting and Anti-Fecundity Effects of Chloramiphene.
Holtkamp, D. E., GRESLIN, J. G., Root, C. A., & Lerner, L. J. (1960) · Experimental Biology and Medicine · doi:10.3181/00379727-105-26054 · Cited by 138
Physical Activity and Risk of Breast Cancer in the Framingham Heart Study
Dorgan, J. F., Brown, C., Barrett, M. J., Splansky, G. L., Kreger, B. E., D’Agostino, R. B., Albanes, D., & Schatzkin, A. G. (1994) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a117056 · Cited by 137
PRACTICAL GUIDE FOR ESTIMATING RISK FOR FAMILIAL BREAST CANCER
Ottman, R., King, M., Pike, M., & Henderson, B. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90580-9 · Cited by 135
Uterine bioassay of tamoxifen, trioxifene and a new estrogen antagonist (LY117018) in rats and mice
Black, L. J., & Goode, R. L. (1980) · Life Sciences · doi:10.1016/0024-3205(80)90049-1 · Cited by 134
Suppression of Mouse Mammary Tumorigenesis by Long-Term Tamoxifen Therapy
Jordan, V. C., Lababidi, M. K., & Langan-Fahey, S. M. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.7.492 · Cited by 134
Self-citationTAMOXIFEN AS AN ANTI-TUMOUR AGENT: EFFECT ON OESTROGEN BINDING
Jordan, V. C., & DOWSE, L. J. (1976) · Journal of Endocrinology · doi:10.1677/joe.0.0680297 · Cited by 133
Self-citationRaloxifene Inhibits Aortic Accumulation of Cholesterol in Ovariectomized, Cholesterol-Fed Rabbits
Bjarnason, N. H., Haarbo, J., Byrjalsen, I., Kauffman, R. F., & Christiansen, C. (1997) · Circulation · doi:10.1161/01.cir.96.6.1964 · Cited by 133
Lieberman, M. E., Gorski, J., & Jordan, V. C. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)32484-0 · Cited by 132
Self-citationSerum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen
Rössner, S., & Wallgren, A. (1984) · Atherosclerosis · doi:10.1016/0021-9150(84)90064-9 · Cited by 132
Risk of familial breast cancer
Anderson, D. E., & Badzioch, M. D. (1985) · Cancer · doi:10.1002/1097-0142(19850715)56:2<383::aid-cncr2820560230>3.0.co;2-0 · Cited by 129
Gottardis, M. M., Ricchio, M. E., SATYASWAROOP, P. G., et al. (1990) · PubMed · Cited by 128
Species-specific pharmacology of antiestrogens: role of metabolism.
Jordan, V. C., & Robinson, S. P. (1987) · PubMed · Cited by 125
Self-citationCoactivators and corepressors as mediators of nuclear receptor function: An update
Jenster, G. W. (1998) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(98)00145-2 · Cited by 125
Ward, R. L., Morgan, G., Dalley, D. N., et al. (1993) · Bone and Mineral · doi:10.1016/s0169-6009(08)80220-6 · Cited by 125
Breast Cancer Risk Factors Among Screening Program Participants
Brinton, L. A., Williams, R. R., Hoover, R. N., Stegens, N. L., Feinleib, M., & Fraumeni, J. F. (1979) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/62.1.37 · Cited by 121
Baum, M., Dossett, J. A., Patterson, J., Smiddy, F. G., Wilson, A. J., Richards, D., Brinkley, D., McPherson, K., Rubens, R. D., Stoll, B. A., et al. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90406-3 · Cited by 121
Katayama, I., & Pechet, L. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92038-3 · Cited by 121
Clinical potential of new antiestrogens.
Gradishar, W., & Jordan, V. C. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.840 · Cited by 120
Self-citationSato, M., Kim, J., Short, L. L., Slemenda, C. W., & Bryant, H. U. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24554-2 · Cited by 119
Skidmore, J. C., Walpole, A. L., & Woodburn, J. R. (1972) · Journal of Endocrinology · doi:10.1677/joe.0.0520289 · Cited by 114
Wen, H. Y., & Brogi, E. (2017) · Surgical pathology clinics · doi:10.1016/j.path.2017.09.009 · Cited by 111
Age at menarche, probability of ovulation and breast cancer risk
MacMahon, B., Trichopoulos, D., Brown, J., Andersen, A. P., Aoki, K., Cole, P. T., Dewaard, F., Kauraniemi, T. V., Morgan, R. W., Purde, M., et al. (1982) · International Journal of Cancer · doi:10.1002/ijc.2910290104 · Cited by 109
The Storage of Estrogen in Human Fat after Estrogen Administration
Greenblatt, R. B., & Brown, N. H. (1952) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(16)38939-6 · Cited by 108
Antiestrogens: Mechanisms and actions in target cells
Katzenellenbogen, B. S., Montano, M. M., Goff, P. L., Schodin, D. J., Kraus, W. L., Bhardwaj, B., & Fujimoto, N. (1995) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(95)00084-d · Cited by 107
Enhancement of human estrogen receptor activity by SPT6: a potential coactivator
Baniahmad, C., Nawaz, Z., Baniahmad, A., Gleeson, M. A., Tsai, M., & O’Malley, B. W. (1995) · Molecular Endocrinology · doi:10.1210/mend.9.1.7760849 · Cited by 105
Sato, M., McClintock, C., Kim, J., Turner, C. H., Bryant, H. U., Magee, D. E., & Slemenda, C. W. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090517 · Cited by 103
Baker, V. L., Draper, M. W., Paul, S., Allerheiligen, S., Glant, M. D., Shifren, J. L., & Jaffe, R. B. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.1.4448 · Cited by 102
Inheritance of Proliferative Breast Disease in Breast Cancer Kindreds
Skolnick, M. H., Cannon‐Albright, L., Goldgar, D. E., Ward, J. H., Marshall, C. J., Schumann, G. B., Hogle, H. H., McWhorter, W. P., Wright, E. C., Tran, T. D., et al. (1990) · Science · doi:10.1126/science.2270486 · Cited by 100
NECROPSY DIAGNOSIS OF ENDOMETRIAL CANCER AND DETECTION-BIAS IN CASE/CONTROL STUDIES
Horwitz, R. I., Horwitz, S. M., Feinstein, A., & Robboy, S. J. (1981) · The Lancet · doi:10.1016/s0140-6736(81)90412-8 · Cited by 99
Jordan, V. C., & Chem, C. (1983) · Breast Cancer Research and Treatment · doi:10.1007/bf01855131 · Cited by 97
Self-citationEFFECTS OF INTENSIVE SEX STEROID HORMONE THERAPY IN ADVANCED BREAST CANCER
Kennedy, B. J. (1953) · JAMA · doi:10.1001/jama.1953.63690120004013 · Cited by 96
Gynecologic effects of tamoxifen and the association with endometrial carcinoma
Assikis, V. J., & Jordan, V. C. (1995) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(95)02387-r · Cited by 94
Self-citationPoulin, R., Merand, Y., Poirier, D., Levesque, C., Dufour, J.-M., & Labrie, F. (1989) · Breast Cancer Research and Treatment · doi:10.1007/bf01805977 · Cited by 86
Jordan, V. C., & Gosden, B. (1982) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(82)90095-8 · Cited by 86
Self-citationPregnancy Termination in Relation to Risk of Breast Cancer
Newcomb, P. A., Storer, B. E., Longnecker, M. P., Mittendorf, R., Greenberg, E. R., & Willett, W. C. (1996) · JAMA · doi:10.1001/jama.1996.03530280035033 · Cited by 86
Catherino, W. H., Wolf, D. M., & Jordan, V. C. (1995) · Molecular Endocrinology · doi:10.1210/mend.9.8.7476979 · Cited by 83
Self-citationLactation and cancer risk: is there a relation specific to breast cancer?
Kvåle, G., & Heuch, I. (1988) · Journal of Epidemiology & Community Health · doi:10.1136/jech.42.1.30 · Cited by 78
Sato, M., Bryant, H. U., Iversen, P. W., Helterbrand, J., Smietana, F. R., Bemis, K. G., Higgs, R. E., Turner, C. H., Owan, I., Takano, Y., et al. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20968-5 · Cited by 69
Risk of cancer of the breast after legal abortion during first trimester: a Swedish register study.
Harris, B., EKLUND, G. A., Meirik, O., Rutqvist, L. E., & Wiklund, K. (1989) · BMJ · doi:10.1136/bmj.299.6713.1430 · Cited by 67
Levenson, A., Tonetti, D. A., & Jordan, V. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.301 · Cited by 63
Self-citationRubin, E., Visscher, D. W., ALEXANDER, R. W., Urist, M. M., & Maddox, W. A. (1988) · Cancer · doi:10.1002/1097-0142(19880515)61:10<2077::aid-cncr2820611024>3.0.co;2-m · Cited by 61
A case—control study of breast cancer and alcohol consumption habits
Young, T. B. (1989) · Cancer · Cited by 58
Œstrous Reactions, including Mating, Produced by Triphenyl Ethylene
Robson, J. M., & Schönberg, A. (1937) · Nature · doi:10.1038/140196b0 · Cited by 49
Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women
Jones, A. L., Powles, T. J., Treleaven, J. G., Burman, J., Nicolson, M. C., Chung, H. I., & Ashley, S. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.350 · Cited by 41
Duration of Action of Natural and Synthetic Œstrogens
Robson, J. M., Schönberg, A., & FAHIM, H. A. (1938) · Nature · doi:10.1038/142292a0 · Cited by 31
Review¶Hormone action and chromatin remodelling
Robyr, D., & Wolffe, A. P. (1998) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050130 · Cited by 23
Comment on Lack of Effect of Raloxifene on Coronary Artery Atherosclerosis of Postmenopausal Monkeys
Bryant, H. U., Kauffman, R. F., Iversen, P. W., et al. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.8.5033-2 · Cited by 10
Cited by
The Multifaceted Mechanisms of Estradiol and Estrogen Receptor Signaling
Hall, J. M., Couse, J. F., & Korach, K. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.r100029200 · Cited by 1,208
TLR7 Ligands Induce Higher IFN-α Production in Females
Berghöfer, B., Frommer, T., Haley, G., Fink, L., Bein, G., & Hackstein, H. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.4.2088 · Cited by 480
Jordan, V. C. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020449y · Cited by 414
Self-citationAlbanito, L., Madeo, A., Lappano, R., Vivacqua, A., Rago, V., Carpino, A., Oprea, T. I., Prossnitz, E. R., Musti, A. M., Andò, S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2909 · Cited by 399
Chemoprevention: an essential approach to controlling cancer
Sporn, M. B., & Suh, N. (2002) · Nature Reviews Cancer · doi:10.1038/nrc844 · Cited by 379
Metadata
- Authors
- Jordan, V. C., & Morrow, M.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 1999-06-01
- Volume
- 20
- Issue
- 3
- Pages
- 253-278
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2133249365
- Cited by
- 258
- References
- 200
- FWCI
- 16.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.